Teva Reports Disappointing ALS Phase II Results for Talampanel

Teva’s talampanel is a no-go for ALS after discouraging Phase II data are reported. Despite demonstrating safety, talampanel did not reach its primary endpoint and will not be advanced as an ALS therapeutic.

Click here to read more.

Share this: